Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma ...

The following is a summary of “Off-label use of biologics in urticarial vasculitis: a European retrospective cohort study,” ...

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical ...

Drawing on 35 years of experience in the development and production of high-temperature ceramic fibre, RATH is always looking ...

A recent study published in the December issue of the Journal of Gastroenterology and Hepatology highlights Vonoprazan's ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

The following is a summary of “Prognostic factors for refractory outcome in localizing TIO: experience in a tertiary center,” ...

LOS ANGELES, CA / ACCESS Newswire / February 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Refractory producer RHI Magnesita has completed its $410 million acquisition of US-based Resco Group, expanding its reach in ...

Panelists discuss how the inclusion of ibrutinib on the Inflation Reduction Act (IRA) negotiated drug price list could make it a more economically attractive first-line option, potentially influencing ...